prostate cancer

MHRA, NHS England make available new prostate cancer treatment
Pharmaphorum
Mon, 11/28/22 - 07:32 pm
Bayer
Orion
prostate cancer
England
Janssen Steps Away from Phase I Prostate Cancer Study, Cites Patient Enrollment Issues
BioSpace
Mon, 10/31/22 - 04:14 pm
Essa Pharma
Janssen
JNJ
prostate cancer
clinical trials
EPI-7386
Janux doses first subject in Phase I prostate cancer therapy trial
Clinical Trials Arena
Thu, 10/13/22 - 09:43 am
Janux Therapeutics
JANX007
prostate cancer
clinical trials
Clarity begins subject dosing in prostate cancer therapy trial
Clinical Trials Arena
Mon, 10/10/22 - 10:55 am
Clarity Pharmaceuticals
prostate cancer
clinical trials
Pfizer’s PARP inhibitor combo treatment passes primary endpoint — but details are slim
Endpoints
Tue, 10/4/22 - 11:06 am
Pfizer
Xtandi
Talzenna
PARP inhibitors
Medivation
clinical trials
prostate cancer
As Rubraca faces questions in ovarian cancer, Clovis trots out a prostate cancer partial win
Fierce Pharma
Mon, 10/3/22 - 11:30 pm
Clovis Oncology
Rubraca
ovarian cancer
prostate cancer
Cardiff drops its lead prostate cancer program, sending shares into a tailspin
Endpoints
Fri, 09/16/22 - 10:09 am
Cardiff Oncology
prostate cancer
ovansertib
China's Jemincare nabs $650M biobucks pact with Roche's Genentech for prostate cancer hopeful
Fierce Biotech
Thu, 08/18/22 - 12:36 pm
Roche
Genentech
China
Jemincare
biobucks
prostate cancer
Orion raises outlook after Merck deal on developing prostate cancer drug
Reuters
Wed, 07/13/22 - 10:40 am
Orion
Merck
prostate cancer
drug development
Advaxis Updates on the Phase 1 Clinical Trial of ADXS-504 for the Treatment of Early Prostate Cancer
BioSpace
Wed, 06/29/22 - 10:53 am
Advaxis
clinical trials
prostate cancer
ADXS-504
New Month, New Collaborations: BMS, Sorrento & Others Announce New Alliances
BioSpace
Fri, 06/3/22 - 09:14 am
Bristol Myers Squibb
Immatics
Sorrento Therapeutics
prostate cancer
clinical trials
Caris Life Sciences
precision medicine
Bayer's Nubeqa one step closer to blockbuster status thanks to FDA priority review in potential new use
Fierce Pharma
Tue, 05/3/22 - 10:48 pm
Bayer
Nubeqa
prostate cancer
AstraZeneca Pushes Deeper into CDx Space with New Collaboration
Medical Devices and Diagnostics Industry
Wed, 04/20/22 - 11:09 am
Medtech
diagnostics
CDx
companion diagnostics
prostate cancer
AstraZeneca
Amoy Diagnostics
A Bayer partner slims down, trimming R&D and enacting layoffs, to better focus on the pair's prostate cancer work
Endpoints
Thu, 03/24/22 - 10:53 am
Orion
Bayer
prostate cancer
layoffs
R&D
Novartis' radiopharma drug wins approval in tough-to-treat prostate cancer patients
Endpoints
Wed, 03/23/22 - 11:01 pm
Novartis
Lu-PSMA-617
radioligand
prostate cancer
Harpoon cuts bait with lead program after failing to find silver linings from ASCO data, other studies
Endpoints
Fri, 03/11/22 - 11:04 am
Harpoon Therapeutics
HPN424
prostate cancer
Oncologists on board for Novartis' prostate cancer radiotherapy, but logistics could hit uptake: survey
Fierce Pharma
Wed, 02/23/22 - 10:29 am
Novartis
prostate cancer
oncologists
radioligand
177Lu-PSMA-617
March-in campaign on Pfizer's prostate cancer med Xtandi gets congressional backing. Will it matter?
Fierce Pharma
Tue, 02/22/22 - 11:17 pm
Pfizer
Astellas
prostate cancer
Xtandi
NIH
ASCO-GU – prostate cancer PARPS move to the front line
EP Vantage
Sun, 02/20/22 - 11:44 am
prostate cancer
ASCO-GU
PARP inhibitors
Lynparza
Zejula
Rubraca
Talzenna
biomarkers
AstraZeneca
Merck
GSK
JNJ
Clovis Oncology
Bayer hikes Nubeqa's peak sales to more than €3B on prostate cancer data, teeing up new 3-way battle against Pfizer-Astellas, J&J
Fierce Pharma
Fri, 02/18/22 - 10:35 am
Bayer
Nubeqa
prostate cancer

Pages